Form 4: ZIVO Director Mark Strome Increases Stake

Mark E. Strome, a Director and 10% owner of Zivo Bioscience, Inc., acquired 20,259 shares of common stock and 2,025 warrants through an affiliated entity.

Summary

• Mark E. Strome, a Director and 10% owner of Zivo Bioscience, Inc. (ZIVO), along with Strome Investment Management LP and Strome Group, Inc., reported the acquisition of ZIVO securities.
• On October 13, 2025, 20,259 shares of ZIVO common stock were acquired at a price of $12.34 per share.
• Additionally, 2,025 common stock purchase warrants were acquired on the same date, with an exercise price of $12.34 and an expiration date of October 12, 2030.
• These securities were acquired by Strome Mezzanine Fund II, LP ("SMF II") pursuant to a Securities Purchase Agreement with Zivo Bioscience, Inc.
• The reporting persons (Mark E. Strome, Strome Investment Management, LP, and Strome Group, Inc.) may be deemed to share voting and investment power and beneficially own the shares held by SMF II.
• Following these transactions, 452,942 shares of common stock and 43,071 common stock purchase warrants are beneficially owned indirectly by the reporting persons.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The acquisition of additional common stock and warrants by a Director and 10% owner, Mark E. Strome, and his affiliated entities, signals strong insider confidence in the company's valuation and future prospects.

Positives

• A Director and 10% owner, Mark E. Strome, along with affiliated entities, increased their beneficial ownership in Zivo Bioscience, Inc.
• The acquisition of 20,259 shares of common stock at $12.34 per share and 2,025 common stock purchase warrants suggests confidence in the company's future.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned acquisition.

Future Outlook

This filing is a transactional report and does not provide explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reported securities are owned directly by Strome Mezzanine Fund II, LP ("SMF II"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer.
• Mark E. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the "Reporting Persons") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934.
• Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.

Industry Context

This Form 4 filing is specific to Zivo Bioscience, Inc. and its insider transactions. It does not provide broader industry trends or competitive analysis. Insider buying can be a signal of confidence within the specific company's sector, but this document does not offer a general industry overview.

Related Party Transactions

• The acquisition of securities by Mark E. Strome, a Director and 10% owner, and his affiliated entities (Strome Investment Management LP, Strome Group, Inc., and Strome Mezzanine Fund II, LP) from Zivo Bioscience, Inc. constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the insider buying as a positive signal, potentially increasing confidence in the company's stock.
• Management: The transaction reinforces alignment between a significant owner/director and the company's equity performance.

Key Dates

Recommendation

The significant acquisition of common stock and warrants by a Director and 10% owner, Mark E. Strome, and his affiliated entities, is a strong indicator of insider confidence. Such a move suggests that those closest to the company believe its shares are undervalued or expect positive developments, making it a compelling signal for potential investors.

Keywords

Zivo Bioscience, ZIVO, Mark Strome, insider buying, Form 4, beneficial ownership, common stock, warrants, equity acquisition, Strome Investment Management, Strome Group